Stada to complete acquisition of Russia's Nizhpharm
This article was originally published in Scrip
Executive Summary
Stadahas asked minority shareholders ofNizhpharm, its subsidiary in Russia, to sell their shares at a price of Rb12,051 ($493.3) each, and Nizhpharm’s board has recommended that they accept the proposal. The German company has owned a 99.1% stake in Nizhpharm, one of Russia’s most advanced pharmaceutical manufacturers, since 2005.